Black Opal Ventures is a venture capital firm that invests in early-phase companies using deep tech and frontier technology to improve healthcare, focusing on the intersection of healthcare and technology.
35% of their portfolio is in Healthcare. Their most common stage is series-a (45% of deals). Average disclosed round size is $53.9M (across 16 rounds with reported amounts).
Portfolio
18
Fund Size
$63M
Top Stage
Series A
Last 12 Mo
5
Team
Dr. Carina Tyrrell, MB BChir, MPH
Founder & Managing Director Select BOV Companies: FlyteHealth, Optellum, Empatica, Conceivabe, Oath, GV20, Chamber
Eileen Tanghal, MBA
Founder & Managing Director Select BOV Companies: Hyro, Outpace, TigerGraph, Blaze, AuthMind, Parasail Select Pre-BOV Companies: Cerebras Systems, Twist Bioscience, Sequans, Paragraf
Eve Castel, CFA
Venture Partner
Franco Danesi, MBA
Venture Partner
Joseph Jeong, PhD
Venture Partner
Hanna Edgren
Chief of Staff & Venture Analyst
Justin Craib-Cox, CFA
Head of Investments
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Thesis Care | Series A | $45M | Mar 2026 |
 Ten63 | Unknown | — | Feb 2026 |
 Chamber Cardio | Series A | $60M | Feb 2026 |
| EEridu AI | Unknown | $200M | Jan 2026 |
| AAnsa Biotechnologies | Series B | $54.4M | Oct 2025 |
 Isaac Health | Series A | $10.5M | Aug 2025 |
 Cyrus | Seed | — | Apr 2025 |
 AuthMind | Seed | $8.5M | Apr 2025 |
| Isaac Health | Series A | $10.5M | Jan 2025 |
| AAuthMind Inc | Seed | $19.3M | Jan 2025 |
 Hyro | Series B | — | Dec 2024 |
 Outpace | Series B | $144M | Aug 2024 |
 FlyteHealth | Series A | $24M | Jan 2024 |
| OOutpace Bio | Series B | $144M | Jan 2024 |
| Hyro | Series B | $20M | May 2023 |
 Empatica | Series B | — | Nov 2022 |
 Optellum | Series A | $14M | Sep 2022 |
 OATH | Series A | $24M | — |
 Chamber | Series A | $60M | — |
| OOath Surgical | Series A | $24M | — |
Top Co-Investors
Last updated: 8 September 2026